^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Nasopharyngeal Carcinoma |
| Drug: | BRG01 (T-cell stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biosyngen’s First-in-class Cell Therapy BRG01 Receives FDA Fast Track Designation
Published date:
07/06/2023
Excerpt:
Biosyngen received an official notification from the U.S. Food and Drug Administration (FDA) granting Fast Track Designation (FTD) to its revolutionary first-in-class immunotherapy, BRG01, for the treatment of relapsed/metastatic nasopharyngeal carcinoma.
